跳至主要内容
临床试验/NCT00001298
NCT00001298已完成1 期

A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction

National Cancer Institute (NCI)1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 1992年3月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
10
试验地点
1

研究概览

简要总结

High dose methotrexate with leucovorin rescue has demonstrated activity in numerous malignancies. Although high dose methotrexate is generally well tolerated, unpredictable life-threatening toxicity can occur. For patients who have markedly delayed clearance of methotrexate secondary to renal dysfunction, therapeutic options are few and are of limited efficacy. Carboxypeptidase-G2 inactivates methotrexate by hydrolyzing its C-terminal glutamate residue. Carboxypeptidase-G2 could be used to rescue patients with renal dysfunction and delayed methotrexate excretion, as it provides an alternative to renal clearance as a route of elimination.

详细描述

High dose methotrexate with leucovorin rescue has demonstrated activity in numerous malignancies. Although high dose methotrexate is generally well tolerated, unpredictable life-threatening toxicity can occur. For patients who have markedly delayed clearance of methotrexate secondary to renal dysfunction, therapeutic options are few and are of limited efficacy. Carboxypeptidase-G2 inactivates methotrexate by hydrolyzing its C-terminal glutamate residue. Carboxypeptidase-G2 could be used to rescue patients with renal dysfunction and delayed methotrexate excretion, as it provides an alternative to renal clearance as a route of elimination.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

性别
All
接受健康志愿者
否

入选标准

  • •Patients of any age at risk for life-threatening toxicity following MTX administration secondary to delayed drug excretion as defined by:
  • •Plasma MTX concentration at least 10 micromoles/liter more than 42 hours after the start of the MTX infusion; OR
  • •Creatinine at least 1.5 times the upper limit of normal or creatinine clearance less than 60 ml/sqm/min and delayed MTX excretion documented by plasma MTX concentration measurements (at least 2 standard deviations above the mean) at least 12 hours following MTX administration.

排除标准

  • 未提供

研究者

申办方类型
Nih

研究点 (1)

Loading locations...

相似试验

A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine... | 临床试验